Figure 1.

G-1 promotes protection against S. aureus SSTI in male mice. WT (C57BL/6J) male mice were treated IP with vehicle (Veh) or 200 ng G-1 on days −2, −1, 0, + 1 and + 2 relative to SQ infection with 2 × 10⁷ CFU of USA300 MRSA isolate LAC. Mice were weighed and lesion size measured daily before mice were sacrificed on day 3 post-infection. (a) Illustration of the G-1 treatment and infection timeline. (b) Representative day 3 post-infection images and area under the curve (AUC) for lesion size (mm²) and (c) percent weight change (relative to pre-infection weight) over the 3-day infection. (d) Day 3 post-infection bacterial burden. (e) IL-1β, TNFα, IL-6, CXCL1 and IL-10 levels and (f) myeloperoxidase levels in clarified injection site homogenate collected on day 3 from the site of infection. Data are mean ± SEM, n = 6–7 mice per group from two independent experiments. Unpaired t-test: ns, not significant; *p < 0.05; **p < 0.01; ***p < 0.001.